A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

June 2, 2021

Study Completion Date

January 10, 2022

Conditions
RRMM
Interventions
DRUG

Melphalan

Peripheral versus central administration

DRUG

Dexamethasone

Oral tablets

Trial Locations (10)

62500

University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno

77900

University Hospital Olomouc, Clinic of Hemato-Oncology, Olomouc

91204

The Oncology Institute of Hope & Innovation - Glendale, Glendale

Unknown

Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Sofia

"Multiprofile Hospital for Active Treatment Sveta Marina, Varna", Varna

Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Budapest

Semmelweis University, 3rd Department of Internal Medicine, Budapest

"Public Non-Profit Enterprise City Clinical Hospital #4 under Dnipro City Council, Regional Hematology Center", Dnipro

"Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Council, Hematology Department #1", Kyiv

Institute of Blood Pathology and Transfusion Medicine, Department of Hematology with Laboratory Group, Lviv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oncopeptides AB

INDUSTRY

NCT04412707 - A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients | Biotech Hunter | Biotech Hunter